Protagonist Therapeutics Inc (PTGX)

Nov 05, 2025

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025 - Leesburg Daily Commercial

Nov 05, 2025

Nov 05, 2025

Is Protagonist Therapeutics Inc. stock entering bullish territory2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - newser.com

Nov 05, 2025

Nov 05, 2025

Bryce Point Capital LLC Invests $343,000 in Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 05, 2025

Nov 05, 2025

How strong is Protagonist Therapeutics Inc. stock revenue growthJuly 2025 Drop Watch & Comprehensive Market Scan Insights - newser.com

Nov 05, 2025

Nov 05, 2025

Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsBuy Signal & Accurate Buy Signal Notifications - newser.com

Nov 05, 2025

Nov 05, 2025

Can Protagonist Therapeutics Inc. hit a new high this monthJuly 2025 Analyst Calls & Verified Momentum Stock Ideas - newser.com

Nov 05, 2025

Nov 05, 2025

How Protagonist Therapeutics Inc. stock reacts to job market data2025 Top Gainers & Technical Pattern Alert System - newser.com

Nov 05, 2025

Nov 04, 2025

Is Protagonist Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Analyst Calls & Real-Time Market Sentiment Reports - newser.com

Nov 04, 2025

Nov 04, 2025

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal - MSN

Nov 04, 2025

Nov 04, 2025

How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Report & Daily Stock Trend Reports - newser.com

Nov 04, 2025

Nov 04, 2025

Protagonist Therapeutics (PTGX): Valuation Insights Ahead of Key Rusfertide Clinical Data at ASH Meeting - Yahoo Finance

Nov 04, 2025

Nov 04, 2025

Rate Hike: How buybacks impact Protagonist Therapeutics Inc. stock valueJuly 2025 WrapUp & Smart Allocation Stock Tips - fcp.pa.gov.br

Nov 04, 2025

Nov 04, 2025

Can Protagonist Therapeutics Inc. stock outperform in 2025 bull marketWeekly Stock Summary & Low Risk High Reward Trade Ideas - fcp.pa.gov.br

Nov 04, 2025

Nov 04, 2025

Hussman Strategic Advisors Inc. Sells 21,000 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat

Nov 04, 2025

Nov 04, 2025

How rising interest rates impact Protagonist Therapeutics Inc. stock2025 Performance Recap & High Accuracy Trade Alerts - newser.com

Nov 04, 2025

Nov 03, 2025

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - ACCESS Newswire

Nov 03, 2025

Nov 03, 2025

Protagonist (PTGX) to present 4 rusfertide presentations at ASH, including Phase 3 VERIFY - Stock Titan

Nov 03, 2025

Nov 03, 2025

Protagonist Therapeutics Inc. stock chart pattern explainedMarket Risk Summary & Fast Moving Market Watchlists - newser.com

Nov 03, 2025

Nov 03, 2025

Leerink Partnrs Issues Optimistic Forecast for PTGX Earnings - MarketBeat

Nov 03, 2025

Nov 02, 2025

Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com

Nov 02, 2025

Nov 01, 2025

Protagonist Therapeutics, Inc. $PTGX is Moody Aldrich Partners LLC's 2nd Largest Position - MarketBeat

Nov 01, 2025

Oct 31, 2025

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Donaldsonville Chief

Oct 31, 2025

Oct 31, 2025

What is Wedbush's Estimate for PTGX FY2029 Earnings? - MarketBeat

Oct 31, 2025

Oct 31, 2025

Protagonist Therapeutics (PTGX) to Release Earnings on Thursday - MarketBeat

Oct 31, 2025

Oct 31, 2025

Will Protagonist Therapeutics Inc. stock benefit from commodity pricesProduct Launch & Daily Entry Point Alerts - newser.com

Oct 31, 2025

Oct 30, 2025

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Asbury Park Press

Oct 30, 2025

Oct 30, 2025

Protagonist Therapeutics (PTGX): Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch - Sahm

Oct 30, 2025

Oct 30, 2025

Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Oct 30, 2025